Following the release of HUTCHMED’s (HCM) FY24 results, we have reviewed our FY25E forecasts and introduce forecasts for FY26E and FY27E. We believe that the growth of HCM’s oncology portfolio will continue to be primarily driven by Fruzaqla in the near term as the drug continues its global rollout, with further growth expected in the US as brand awareness builds and Fruzaqla pushes into 3L patients. We have updated our forecasts to reflect the delayed launch of sovleplenib in China, which is no ....
